The Royal Pharmaceutical Society (RPS) has launched a new national learning programme, developed in collaboration with Idorsia Pharmaceuticals UK Ltd, to support pharmacists in identifying and managing patients with insomnia.
Designed for pharmacists working across primary and secondary care, the programme covers both acute and chronic insomnia, including its impact on co-morbidities such as mental health conditions and chronic pain.
The programme follows a blended learning approach and will include webinars, podcasts and e-learning modules to support and enrich learning.
The programme launches in October, starting with the first in a series of webinars:
Additional content – including three patient-focused podcasts and three e-learning modules – is currently in development and will be released via RPS Learn later this year and into early 2026.
Helen Chang, RPS Head of Professional Development, said:
“We’re proud to collaborate with partners and experts like Idorsia to develop education that is high-quality, evidence-based and supports pharmacists directly in practice. Sleep health is a vital part of patient wellbeing, and pharmacists are in a key position to support those experiencing insomnia. This programme equips pharmacists with the skills and confidence to help meet this need.”
The insomnia learning programme forms part of the RPS’s 2025 education plan and aligns with wider NHS goals around improving sleep health, reducing inappropriate prescribing and empowering patients to self-care.
The content for the webinars and all associated materials have been developed under a collaborative working agreement between RPS and Idorsia Pharmaceuticals UK Ltd. Idorsia Pharmaceuticals UK Ltd has provided funding for this initiative and has reviewed and certified the materials in accordance with the ABPI Code of Practice.
UK-IDS-00087 | September 2025